Researchers at The University of Texas MD Anderson Cancer Center have mapped the spatial architecture of muscle-invasive bladder cancer, identifying how tumor cell states and immune environments interact within specific regions of a tumor. Published in Cancer Discovery, the study reveals that bladder cancer is not a uniform disease, but a complex landscape where luminal and basal-like cell states coexist, offering a new framework for precision therapy selection.
How does the spatial map change our understanding of bladder cancer?
Traditional molecular subtyping has historically classified bladder cancer into two categories: luminal or basal. However, the MD Anderson team found this binary model fails to capture the full picture. According to Linghua Wang, M.D., Ph.D., the study demonstrates that these distinct cell states exist within the same tumor in highly organized, physical patterns.

By integrating spatial transcriptomics from 22 pretreatment tumors with whole-exome and single-cell sequencing, researchers identified a continuous differentiation axis. Luminal-like cells, which are enriched for markers like FGFR3 and NECTIN4, typically occupy the tumor core. Conversely, basal-like cells—characterized by EGFR signaling and higher chromosomal instability—predominate near the invasive margins of the tumor.
The research team validated these spatial findings across more than 3,000 independent bladder cancer tumors, confirming that the physical location of cells is a reliable indicator of their biological behavior and aggressiveness.
What are the implications for future treatment strategies?
The study suggests that future clinical approaches should move away from treating bladder cancer as a uniform entity. Jianjun Gao, M.D., Ph.D., professor of Genitourinary Medical Oncology, notes that effective care may require targeting both the luminal and basal components within the same patient.

- NECTIN4-targeted therapies: Because luminal regions show high NECTIN4 expression, drugs like enfortumab vedotin are better suited for these specific tumor cores.
- Chemotherapy and immunotherapy: Basal-like margins exhibit higher immune infiltration, suggesting these regions may respond more favorably to chemotherapy or immunotherapy-based regimens.
By identifying these lineage-specific vulnerabilities, clinicians could eventually use spatial data to sequence therapies, hitting distinct tumor compartments with the most effective agents for that specific region.
What happens next in clinical research?
The next phase of research focuses on validating these findings in larger, prospective clinical cohorts. While the current data provides a roadmap for pretreatment tumor analysis, researchers must now determine how these spatial architectures shift over time during treatment.
Post-treatment samples will be critical to understanding if therapy reshapes the tumor’s “map” or if residual cells adopt new states. According to the MD Anderson team, this longitudinal data is essential for transitioning from static snapshots to dynamic, adaptive treatment plans that account for tumor evolution.
If you are tracking advancements in oncology, look for clinical trials that incorporate spatial transcriptomics. These studies are increasingly used to explain why patients with similar genetic profiles often experience different outcomes when receiving the same standard-of-care drugs.
Frequently Asked Questions
Why do some bladder cancer patients respond better to treatment than others?
According to MD Anderson researchers, varying responses are likely linked to the spatial organization of the tumor. Because tumors contain diverse cell states in different regions, a drug that works on the tumor core may not be effective at the invasive margin.

What is the difference between luminal and basal-like tumor cells?
Luminal cells are typically found in the tumor core and express FGFR3 and NECTIN4. Basal-like cells are found at the invasive margins, showing higher EGFR signaling and increased immune infiltration.
Can spatial mapping be used in clinical practice today?
Not yet. The current findings provide a framework for future biomarker development. Prospective clinical trials are required to validate these findings before they become part of standard diagnostic or treatment protocols.
Are you interested in the latest breakthroughs in cancer research? Subscribe to our newsletter for updates on precision oncology and emerging therapeutic technologies.











